Cost barriers keep RSV protection out of South Africa's public health system

Newly approved maternal RSV vaccines and antibody treatments are not being adopted in South Africa's public healthcare system due to high costs, leaving vulnerable infants unprotected. The gap between private availability and public access highlights inequity in vaccine rollout. This matters as RSV is a leading cause of infant hospitalization and mortality in low- and middle-income countries.